60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.
60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.
Price: 1.17, Change: -0.10, Percent Change: -7.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。